



OPEN ACCESS

**Edited by:**

Herbert Leonel de Matos Guedes,  
Federal University of Rio de  
Janeiro, Brazil

**Reviewed by:**

Muhammad Imran Khan,  
The University of Haripur, Pakistan  
Mehmet Karakus,  
University of Health Sciences, Turkey  
Yusuf Ozbel,  
Ege University, Turkey

**\*Correspondence:**

Homa Hajjaran  
hajaranh@tums.ac.ir  
Reza Saberi  
r.saberi@mazums.ac.ir

**†ORCID:**

Homa Hajjaran  
orcid.org/0000-0001-5877-2845  
Reza Saberi  
orcid.org/0000-0002-7906-7034  
Alireza Borjian  
orcid.org/0000-0003-1440-4922  
Mahdi Fakhar  
orcid.org/0000-0002-4690-6938  
Seyed Abdollah Hosseini  
orcid.org/0000-0002-2990-1123  
Mehdi Mohebbali  
orcid.org/0000-0002-4164-9514

**Specialty section:**

This article was submitted to  
Infectious Diseases - Surveillance,  
Prevention and Treatment,  
a section of the journal  
Frontiers in Public Health

**Received:** 31 January 2021

**Accepted:** 31 May 2021

**Published:** 25 June 2021

**Citation:**

Hajjaran H, Saberi R, Borjian A,  
Fakhar M, Hosseini SA, Ghodrati S  
and Mohebbali M (2021) The  
Geographical Distribution of Human  
Cutaneous and Visceral Leishmania  
Species Identified by Molecular  
Methods in Iran: A Systematic Review  
With Meta-Analysis.  
Front. Public Health 9:661674.  
doi: 10.3389/fpubh.2021.661674

# The Geographical Distribution of Human Cutaneous and Visceral Leishmania Species Identified by Molecular Methods in Iran: A Systematic Review With Meta-Analysis

Homa Hajjaran<sup>1\*†</sup>, Reza Saberi<sup>2,3\*†</sup>, Alireza Borjian<sup>1†</sup>, Mahdi Fakhar<sup>2†</sup>,  
Seyed Abdollah Hosseini<sup>2†</sup>, Sajjad Ghodrati<sup>1</sup> and Mehdi Mohebbali<sup>1†</sup>

<sup>1</sup> Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran, <sup>2</sup> Toxoplasmosis Research Center, Communicable Diseases Institute, Iranian National Registry Center for Lophomoniasis and Toxoplasmosis, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran, <sup>3</sup> Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran

Leishmaniasis is one of the most common vector-borne parasitic disease in Iran. *Leishmania* species identification is necessary for epidemiological aspects, precise prognosis, control and treatment of the disease. We systematically searched all the studies, reports, and documentation related to species identification and geographical distribution of causative agents of cutaneous (CL), mucosal (ML), and visceral leishmaniasis (VL) using DNA-based molecular diagnostic techniques in Iran. International databases including PubMed, ScienceDirect, Embase, Google Scholar, Scopus, and Web of Science were systemically searched for English articles and Iran's databases including SID, IranMedex and Magiran were searched for Persian reports and articles. Searches were performed from 1999 to 2019 (20 years). The current review was conducted using the keywords: cutaneous leishmaniasis, visceral leishmaniasis, *Leishmania* species, Human, Molecular, PCR, and Iran. The study quality was evaluated using the NOS checklist. This meta-analysis procedure was accomplished using STATA, version 2.7.9. Of the 3,426 records identified in the initial search, 154 articles met inclusion criteria and qualified for the systematic review and meta-analysis. In subgroup analysis, the pooled frequency of causative agents of CL isolates was 67.3% (95% CI: 59.51–74.67%) for *L. major* and 32.1% (95% CI: 24.72–39.87%) for *L. tropica*. In addition, the pooled frequency of causative agents of VL isolates was 97.1% (95% CI: 94.6–98.8%) for *L. infantum* and 2.9% (95% CI: 1.12–5.37%) for *L. tropica*. The findings of this study showed that the main causative agents of CL and VL in Iran are *L. major* and *L. infantum*, respectively. Moreover, kinetoplast DNA (kDNA) and internal transcriber spacer (ITS) were the most used markers for identifying *Leishmania* species. The current study provides valuable data to encourage and direct researchers as well

as public health managers in the comprehensive leishmaniasis control and prevention planning in Iran.

**Keywords:** *Leishmania major*, *Leishmania tropica*, *Leishmania infantum*, DNA-based molecular method, human, Iran

## INTRODUCTION

Leishmaniasis is a neglected tropical disease (NTD) caused by the *Leishmania* parasites, which are transmitted by the bite of sand flies (1). There are four clinical forms of the disease: cutaneous leishmaniasis (CL), visceral leishmaniasis (VL), and mucocutaneous leishmaniasis (MCL) and mucosal leishmaniasis (ML) (2). Despite universal scientific community efforts to reduce cases of human leishmaniasis, numerous cases of such devastating disease are still reported worldwide (3). The disease currently affects 12 million people with 350 million people are living in regions with a high risk of infection. World Health Organization (WHO) estimates the annual global incidence of 0.7–1.2 million cases of CL and 0.1–0.4 million cases of VL (4). At present, the majority (about 90%) of CL cases occur in eight countries mainly including Asian and South American countries (4). Moreover, more than 90% of global cases of VL had been reported from seven countries mainly including African and South American countries (4, 5). In Iran, CL is the most common form of the disease and recent reports estimates >20,000 annual cases (6), but VL has been reported sporadically, with about 100–300 new serologically positive cases of VL reported annually (7).

Species discrimination is important, because of differences among the *Leishmania* species in levels of virulence and responses to the various chemical drugs (8, 9). As a result, distinguishing *Leishmania* spp. is critical for accurate diagnosis and appropriate treatment (9). Morphological identification of *Leishmania* species is not possible, but a variety of DNA-based molecular diagnostic techniques, including restriction fragment length polymorphism (RFLP), nested-PCR methods as well as high-resolution melting analysis PCR (HRM-PCR) have been reported for identification of *Leishmania* on different taxonomical levels (genus and species) (10). According to our literature review, several target markers were used to identify *Leishmania* species, including minicircle kinetoplastic DNA, heat shock protein 70 gene, N-acetylglucosamine-1-phosphate transferase (nagt) gene, and internal transcription spacer (ITS1 & 2).

There are several studies regarding the identification of *Leishmania* species causing CL and VL in Iran. The aim of this systematic review and meta-analysis was therefore to define the geographical distribution of *Leishmania* spp. among human populations as well as exploring molecular markers used for identifying *Leishmania* spp. in this population throughout two decades ago (1999–2019) in Iran.

## METHODS

### Search Approach

This systematic study was achieved according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis

(PRISMA) (11). The present study was carried out to estimate the species identification and geographical distribution of causative agents of CL and VL cases in Iran. A search in literature was carried out via the nine English and Persian databases, including PubMed, Embase, Google Scholar, Science Direct, Scopus, Web of Science and SID, IranMedex and Magiran up to Sep 2019, respectively. The current review was conducted by the Medical Subject Headings (MeSH) terms including: “Cutaneous leishmaniasis”, “Visceral leishmaniasis,” “*Leishmania*”, “Species”, “Human,” “Molecular”, “PCR”, and “Iran”, alone or combined together with “OR” or/and “AND” operators.

### Paper Screening

Initially, the titles and abstracts of searched articles were screened for eligibility by two authors independently, and those that did not describe identification of *Leishmania* species were removed. Data on the identification of *Leishmania* spp., were extracted from studies according to the following including criteria: (a) peer-reviewed original research, (b) papers studies that surveyed identification of *Leishmania* species using various polymerase chain reaction techniques, (c) studies published in English or Persian during 1999–2019 and (d) full-text articles were available. Additionally, the exclusion criteria were as follows; (a) duplicated data, (b) review studies, and (c) studies on animal reservoirs.

### Data Extraction

Out of the retrieved papers, 154 papers were eligible for inclusion in this study. Required data were collected based on the first author, publication year, province, total sample, positive number, *Leishmania* spp., types of clinical manifestation, diagnostic methods, marker genetic used and quality assessment. Three independent authors extracted the above details carefully.

### Quality Assessment

In the current study, the Newcastle-Ottawa Scale was used to evaluate the quality of studies. NOS score ranged from 0 and 7 [low quality, (1 and 2), moderate quality, (3–5), and high quality (6 and 7)] (12).

### Statistical Analysis

This meta-analysis was completed using STATA software, as comprehensive meta-analysis software (<http://statsdirect.com>). The heterogeneity index was assessed using standard Cochran’s Q- and I-squared statistics, with the random effects estimate they imply. Egger’s test was used to assess potential publication bias. A  $p < 0.05$  ( $\leq 0.05$ ) is statistically significant.

## RESULTS

### Characteristics and Quality of the Included Studies

Records retrieved in the mentioned electronic databases based on preparatory search strategies of nine databases yielded 3,426 papers; after removal of duplication papers, 2,244 papers were extracted. In the next step, using the abstract screening based on the inclusion/exclusion criteria, 1,683 other articles were excluded. Following that, 561 full-text articles were screened, of which 154 were found to be eligible for systematic review and meta-analysis. **Figure 1** summarizes the flow chart presenting the study design process. The baseline characteristics of all included studies are tabulated in **Tables 1, 2**.

### Results of the Meta-Analysis

In total, 10,586 CL isolates were identified, with two causatives of ZCL (*L. major*,  $n = 6,714$ ) and ACL (*L. tropica*,  $n = 3,872$ ) being reported in 19 provinces across Iran (Fars, Khuzestan, Isfahan, Golestan, Ilam, Razavi Khorasan, Kerman, Sistan & Balochistan, Tehran, Yazd, Hormozgan, Semnan. Most of the *L. major* isolates belonged to Fars ( $n = 992$ ), Khuzestan ( $n = 844$ ), and Isfahan ( $n = 687$ ) provinces in the southern and central regions of Iran. In addition, the majority of *L. tropica* isolates belonged to Kerman ( $n = 1,142$ ), Razavi Khorasan ( $n = 949$ ) in the east, and Lorestan ( $n = 260$ ) in the west (**Figure 2**). In contrast, 542 isolates for VL cases were determined in 11 provinces (Fars, Ardabil, Tehran, Kohgiluyeh and Boyer-Ahmad, Golestan, Ilam, Lorestan, East-Azerbaijan, Boushehr, Kerman, and Mazandaran), with the majority of VL isolates belonging to Fars ( $n = 230$ ) in southwestern Iran and Ardabil ( $n = 107$ ) in northwestern Iran (**Figure 3**).

According to the literature review, nine genetic markers (kinetoplast DNA, internal transcribed spacer region-1 and 2, cytochrome b, heat shock protein 70, N -acetylglucosamine-1-phosphate transferase, pteridine reductase 1, trypanothione peroxidase, Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) and 7SL RNA) were used for identification *Leishmania* species that the most species were identified with kinetoplast DNA ( $n = 5,592$ ) and ITS markers ( $n = 4,544$ ). It should be noted that some species of *Leishmania* were identified by Random amplified polymorphic deoxyribonucleic acid analysis by PCR (RAPD-PCR) method using random primers. The used molecular methods of *Leishmania* species identification in most studies were nested PCR and PCR-RFLP.

In subgroup analysis, the pooled frequency of causative agents of CL isolates was 67.3% (95% CI: 59.51–74.67%) for *L. major* and 32.1% (95% CI: 24.72–39.87%) for *L. tropica* (**Table 3** and **Supplementary Figures 1, 2**). Also of note, the 14 and four isolates were identified as *L. infantum* and *L. turanica* as causative agents of CL and ZCL cases, respectively (14, 22, 36, 47, 74, 89, 120, 122).

In addition, the pooled frequency of causative agents of VL isolates was 97.1% (95% CI: 94.6–98.8%) for *L. infantum* and 2.9% (95% CI: 1.12–5.37%) for *L. tropica* (**Table 3** and **Supplementary Figures 3, 4**). Also, other clinical forms of leishmaniasis were reported as follow: ML ( $n = 12$ ), DCL ( $n =$

5), MCL ( $n = 3$ ), and PKDL ( $n = 2$ ). ML cases caused by *L. major* ( $n = 7$ ), *L. tropica* ( $n = 2$ ), *L. infantum* ( $n = 2$ ), and a mix of *L. major/L. tropica* ( $n = 1$ ) whereas, all DCL and MCL cases caused by *L. major*, but two causative agents of PKDL were identified as *L. infantum*.

## DISCUSSION


Leishmaniasis remains a major community health-based challenge with worldwide distribution, particularly in Iran (165). Identification of species is essential in diagnosis, treatment and epidemiological studies (165). We attempted to determine the etiological agents of human cutaneous and visceral leishmaniasis and their geographical distribution in Iran over two decades ago in the current systematic review and meta-analysis study.

According to the finding of the meta-analysis, most *Leishmania* isolates identified in Iran belonged to CL than VL cases. Every year, a large number of CL cases with a wide distribution are reported in 19 of 31 Iranian provinces, primarily in the central, southwest, east, and northeast regions. Some evidence suggests that the CL incidence rate overall has been decreasing in recent years, from 37/100,000 in 2007 to 22/100,000 in 2013. This decrease in incidence could be because appropriate public health measures such as education to residents, case finding and management, treatment, control of reservoir hosts, and distribution of repellents and nets treated with permethrin in the endemic focus of the disease have been accomplished (166).

However, at the same time, it seems like the distribution of CL has been extended to a new area (166, 167). In contrast, VL is mainly endemic in restricted regions of Iran, notably the northwest (Ardabil province) and southwest (Fars province) (7).

As illustrated by the finding of the subgroup analysis, the pool frequency of *L. major* and *L. tropica*, as causative agents of CL was 67.32% (95% CI: 59.51–74.67%) and 32.1% (95% CI: 24.72–39.87%), respectively. It can be concluded that the distribution of ZCL is higher than ACL form. According to a systematic review study conducted by Foroutan et al. rodents are the most important reservoirs of *Leishmania* species in many foci of ZCL throughout Iran (168). The most important of these rodent reservoirs are *Rhombomys opimus*, *Meriones libycus*, and *Nesokia indica*. The finding of this study showed that *L. major* has been reported as the predominant species of these rodents. The role of rodents in the spread of ZCL is evident (168).

The findings of this study demonstrated that the main causative agent of ZCL cases in the 14 provinces is *L. major* and the main causative agent of ACL cases in the five provinces is *L. tropica* (**Figure 2**). Although *L. tropica* was formerly common in many large urban areas, it has also been observed in rural areas and small cities in Iran (169). According to the findings of the two studies, four isolates of *L. turanica* were found in CL patients in the Gonbad-Kavous and Turkmen Sahara districts of Golestan province, which are the known oldest ZCL foci (90, 121). Nevertheless, it should be noted that *L. major* is the principal agent of ZCL in Iran. Besides, 14 isolates of *L. infantum* have been reported to cause CL cases (14, 22, 36, 47, 74, 122). A review of the literature showed that cases of *L. infantum* as



the causative agent of CL have previously been identified in the Mediterranean (170), Southeast European countries, such as Portugal, Spain, Italy, and France (171) and the Americas (172), which is consistent with the findings.

On the other hand, the pool frequency of causative agents of VL isolates was 97.1% (95% CI: 94.6–98.8%) for *L. infantum* and 2.9% (95% CI: 1.12–5.37%) for *L. tropica*. The result of this study revealed that the main causative agent of VL in Iran is *L. infantum*. According to the results of a recent systematic review, the prevalence of HVL infection has been decreased in Iran throughout the last two decades. The maximum (3%, 95% CI: 1–5%) and minimum (0.5%, 95% CI, 0.2–0.7%) pooled prevalence of HVL was estimated in the northern and western Iranian provinces, respectively (173). It should be noted that the reason for reporting the relatively high number of cases of VL in Tehran, central Iran, as shown in **Figure 3**, is that these patients

were referred to Tehran University Hospitals from other regions for diagnosis and treatment follow-up. Therefore, these reported cases did not belong to Tehran.

Nonetheless, despite the Iranian Center for Disease Control's (CDC) efforts to monitor and prevent HVL, new human cases of VL continue to emerge in old endemic foci. On the other hand, the disease has also emerged in new non-endemic areas of the country, such as Golestan province in north-eastern Iran (174). However, geo-climatic and environmental factors play the most important role in the emergence/reemergence of HVL in an area (174). Reasonable steps to monitor VL and prevent its spread to other areas should be taken in this respect.

Currently, molecular approaches are used for species identification, genotyping, and determine polymorphisms in *Leishmania* parasites (175). In most cases, these methods have

**TABLE 1** | Baseline characteristics of the *Leishmania* species identification from CL cases in the systematic review and meta-analysis from 1999 to 2019.

References	Years	Province	Number samples	Species		PCR type	Used genetic marker	NOS score
				<i>L. major</i>	<i>L. tropica</i>			
Alimohammadian et al. (13)	1999	Isfahan	8	8	0	PCR	kDNA	5
Motazedian et al. (14)	2002	Iran (Several province) <sup>a</sup>	78	42	36	RAPD-PCR	Random Primers	3
Tashakori et al. (15)	2003	Iran (Several province) <sup>b</sup>	67	45	22	PCR	kDNA	4
Hajjaran et al. (16)	2004	Razavi Khorasan	87	5	82	RAPD-PCR	Random Primers	4
Motazedian et al. (17)	2004	Fars	47	27	20	Nested PCR	kDNA	4
Hadighi et al. (18)	2006	Razavi Khorasan	31	3	28	PCR	PTR1	3
Tashakori et al. (19)	2006	Iran (Several province) <sup>c</sup>	24	24	0	RFLP	ITS_1&2	5
Akhavan et al. (20)	2007	Kerman	2	2	0	RAPD-PCR	Random primers	3
Maraghi et al. (21)	2007	Khuzestan	100	90	10	Nested PCR	kDNA	4
Kazemi rad et al. (22)	2008	Tehran	31	14	17	RFLP	ITS_1	6
Shahbazi et al. (23)	2008	Razavi Khorasan	86	3	83	RFLP	ITS_1	4
Fazaeli et al. (24)	2008	Sistan and Baluchestan	51	51	0	PCR	kDNA	4
Mohajery et al. (25)	2008	Razavi Khorasan	57	0	57	RAPD-PCR	Random primers	4
Alimoradi et al. (26)	2009	Kermanshah	20	17	3	RAPD-PCR	Random primers	3
Rahbarian et al. (27)	2009	Golestan	46	46	0	PCR	ITS_1&2	5
Razmjou et al. (28)	2009	Fars	27	27	0	Nested PCR	kDNA	6
Emami et al. (29)	2009	Isfahan	28	28	0	RAPD-PCR	Random primers	4
Fazaeli et al. (30)	2009	Sistan and Baluchestan	41	41	0	PCR	kDNA	4
Khalili et al. (31)	2009	Kerman	55	0	55	RFLP	ITS_1	5
Khalili et al. (31)	2009	Fars	28	1	27	RFLP	ITS_1	4
Pirstani et al. (32)	2009	Razavi Khorasan	54	17	37	RFLP	ITS_1	3
Sharifi et al. (33)	2010	Kerman	9	0	9	PCR	kDNA	4
Doudi et al. (34)	2010	Isfahan	209	205	4	RFLP	ITS_1	3
Doudi et al. (34)	2010	Kerman	122	50	72	RFLP	ITS_1	3
Saki et al. (35)	2010	Khuzestan	60	58	2	RFLP	kDNA	5
Pourmohammadi et al. (36)	2010	Fars	204	196	8	PCR	kDNA	4
Mahmoodi et al. (37)	2010	Razavi Khorasan	21	2	19	PCR	kDNA	4
Mesgarian et al. (38)	2010	Golestan	46	46	0	PCR	ITS_1&2	5
Mohajery et al. (39)	2010	Razavi Khorasan	86	54	32	PCR	kDNA	4
Fakhar et al. (40)	2010	Fars	35	35	0	PCR	kDNA	4
Hamzavi et al. (41)	2010	Kermanshah	7	7	0	RAPD-PCR	RP	3
Ghasemian et al. (42)	2011	Khuzestan	100	97	3	Nested PCR	kDNA	4
Farahmand et al. (43)	2011	Tehran	50	32	18	PCR	kDNA	4
Hajjaran et al. (44)	2011	Tehran	51	32	19	RFLP	ITS_1	7
Sharifi et al. (45)	2011	Kerman	26	0	26	PCR	kDNA	6
Sharifi et al. (46)	2011	Kerman	66	0	66	PCR	kDNA	6
Khademvatan et al. (47)	2011	Khuzestan	95	90	5	RT-PCR	kDNA	5
Azani et al. (48)	2011	Semnan	25	25	0	RFLP	ITS_1	3
Pour et al. (49)	2011	Kerman	51	0	51	Nested PCR	kDNA	4
Azani et al. (50)	2011	Semnan	57	57	0	Nested PCR	kDNA	4
Poursmaelian et al. (51)	2011	Kerman	188	0	188	Nested PCR	kDNA	5
Azizi et al. (52)	2012	Hormozgan	18	18	0	Nested PCR	kDNA	4
Khosravi et al. (53)	2012	Isfahan	79	75	4	RT-PCR	Tryparedoxin reoxidase	3

(Continued)

TABLE 1 | Continued

References	Years	Province	Number samples	Species		PCR type	Used genetic marker	NOS score
				<i>L. major</i>	<i>L. tropica</i>			
Sharifi et al. (54)	2012	Kerman	203	9	194	Nested PCR	kDNA	4
Mahmoudzadeh et al. (55)	2012	Iran (Several province) <sup>d</sup>	341	283	58	PCR	kDNA	3
Shiee et al. (56)	2012	Isfahan	63	5	58	RFLP	ITS_1	4
Hashemi et al. (57)	2012	Isfahan	50	46	4	RFLP	ITS_1	4
Mirzaei et al. (58)	2012	Kerman	26	0	26	Nested PCR	kDNA	5
Mohammadi et al. (59)	2012	Isfahan	60	60	0	RFLP	ITS_1	4
Saghafipour et al. (60)	2012	Qom	15	15	0	RFLP	ITS_1	3
Baghaei et al. (61)	2012	Fars	32	31	1	RFLP	ITS_1	4
Baghaei et al. (62)	2012	Golestan	90	90	0	RFLP	ITS_1	4
Kazemi rad et al. (63)	2013	Razavi Khorasan	2	0	2	RFLP	ITS_1	3
Akhundi et al. (64)	2013	Fars	42	39	3	RFLP	ITS_1	4
Sharif maraghi et al. (65)	2013	Khuzestan	146	138	8	Nested PCR	kDNA	4
Kheirandish et al. (66)	2013	Lorestan	178	49	129	PCR	ITS_1	4
Yaghoobi Ershadi et al. (67)	2013	Bushehr	8	2	6	Nested PCR	ITS_1	5
Kheirandish et al. (68)	2013	Lorestan	62	17	45	PCR	ITS_1	4
Saadabadi et al. (69)	2013	Razavi Khorasan	22	0	22	RAPD-PCR	RP	3
Hajjaran et al. (70)	2013	Iran	114	75	39	RFLP	ITS_1	5
Oryan et al. (71)	2013	Fars	98	97	1	Nested PCR	kDNA	4
Aflatoonian et al. (72)	2013	Kerman	66	0	66	PCR	kDNA	4
Taghizadeh et al. (73)	2013	Isfahan	123	111	12	PCR	kDNA	5
Badrizadeh et al. (74)	2013	East Azerbaijan	12	12	0	Nested PCR	kDNA	4
Hoseini Farash et al. (75)	2013	Razavi Khorasan	136	0	136	PCR	kDNA	6
Mohammadi et al. (76)	2013	Tehran	255	147	108	PCR	ITS_2	5
Beiranvand et al. (77)	2013	Lorestan	52	50	2	Nested PCR	kDNA	5
Karamian et al. (78)	2013	South Khorasan	80	8	72	RFLP	ITS_1	3
Pagheh et al. (79)	2013	Golestan	50	50	0	PCR	kDNA	4
Mirzaie et al. (80)	2013	Yazd	102	50	52	RFLP	ITS_1	5
Spotin et al. (81)	2014	Khuzestan	99	90	9	RFLP	ITS_1,Cyt b,rDNA	6
Tolouei et al. (82)	2014	Isfahan	28	28	0	PCR	ITS_1	5
Shirian et al. (83)	2014	Fars	98	97	1	Nested PCR	kDNA	4
Salehi et al. (84)	2014	Razavi Khorasan	35	4	31	PCR	kDNA	4
Hajjaran et al. (9)	2014	Iran (Several province) <sup>e</sup>	77	36	41	RFLP	NAGT	6
Eslami et al. (85)	2014	Yazd	102	50	52	RFLP	ITS_1	3
Arjmand et al. (86)	2014	Isfahan	50	50	0	Nested PCR	ITS_1	4
Hassanpour et al. (87)	2014	Razavi Khorasan	86	54	32	PCR	kDNA	4
Ghatee et al. (88)	2014	Fars	31	22	9	PCR	ITS_1	4
Ghatee et al. (88)	2014	Kerman	119	0	119	PCR	ITS_1	4
Bordbar et al. (89)	2014	Golestan	123	123	0	RFLP	ITS_1&2	5
Moravvej et al. (90)	2014	Tehran	8	8	0	PCR	kDNA	4
Karimian Shirazi et al. (91)	2014	Razavi Khorasan	100	6	94	Semi-nested	kDNA	4
Abdolmajid et al. (92)	2015	Razavi Khorasan	66	20	46	PCR	kDNA	5
Shamsian et al. (93)	2015	Razavi Khorasan	64	52	12	PCR	kDNA	4
Spotin et al. (94)	2015	Khuzestan	97	97	0	RFLP	ITS_1,Cyt b	5
Mohebbali et al. (95)	2015	Bushehr	21	14	7	RFLP	ITS_1	7
Doroodgar et al. (96)	2015	Isfahan	14	10	4	RAPD-PCR	RP	4
Kolivand et al. (97)	2015	Tehran	15	15	0	PCR	kDNA	3
Gholami et al. (98)	2015	Ilam	50	50	0	RFLP	ITS_1	4
Hezari et al. (99)	2016	Golestan	38	38	0	RFLP	ITS_1	5

(Continued)

TABLE 1 | Continued

References	Years	Province	Number samples	Species		PCR type	Used genetic marker	NOS score
				<i>L. major</i>	<i>L. tropica</i>			
Haddad et al. (100)	2016	Ilam	92	92	0	Nested PCR	kDNA	4
Naseri et al. (101)	2016	Razavi Khorasan	60	7	53	PCR	kDNA	4
Ghasemloo et al. (102)	2016	Isfahan	70	10	60	RFLP	ITS_1	4
Rasti et al. (103)	2016	Isfahan	96	26	70	Nested PCR	kDNA	4
Mirahmadi et al. (104)	2016	Sistan and Baluchestan	64	11	53	RFLP	Hsp70	5
Dabirzadeh et al. (105)	2016	Sistan and Baluchestan	19	19	0	RFLP	ITS_1	6
Sharifi rad et al. (106)	2016	Sistan and Baluchestan	35	35	0	PPIP-PCR	kDNA	4
Sarkari et al. (107)	2016	Fars	77	57	20	RFLP	NAGT	5
Abedi-Astaneh et al. (108)	2016	Qom	9	9	0	RFLP	ITS_1	6
Hajjaran et al. (109)	2016	Tehran	43	24	19	RFLP	ITS_1	5
Izadi et al. (110)	2016	Fars	54	49	5	Nested PCR	kDNA	4
Izadi et al. (110)	2016	Isfahan	25	25	0	Nested PCR	kDNA	4
Karamian et al. (111)	2016	South Khorasan	60	5	55	RFLP	ITS_1	4
Mohammadpour et al. (112)	2016	Fars	6	4	2	PCR	kDNA	4
Soltan et al. (113)	2016	Khuzestan	97	97	0	RFLP	ITS_1, Cyt b, rDNA	3
Pazoki Ghohe et al. (114)	2016	Tehran	57	57	0	PCR	kDNA	4
Rezai et al. (115)	2017	Razavi Khorasan	84	16	68	PCR	kDNA	5
Kermanjani et al. (116)	2017	Ilam	61	61	0	RFLP	ITS_1	5
Mohammadiha et al. (117)	2017	Razavi Khorasan	94	33	61	RFLP	ITS_1	3
Nemati et al. (118)	2017	Iran (Several province)f	24	15	9	RFLP	Hsp70	5
Motalleb et al. (119)	2017	Sistan and Baluchestan	100	53	47	RFLP	Cyt b	4
Esmaeili Rastaghi et al. (120)	2017	Golestan	87	85	2	RFLP	ITS_1	4
Esmaeili Rastaghi et al. (120)	2017	Khuzestan	87	87	0	RFLP	ITS_1	4
Esmaeili Rastaghi et al. (120)	2017	Yazd	52	48	4	RFLP	ITS_1	4
Behravan et al. (121)	2017	Tehran	44	37	7	RFLP	ITS_1	4
Mohammadpour et al. (122)	2017	Fars	6	3	3	PCR	kDNA	3
Saghaipour et al. (123)	2017	Qom	45	45	0	RFLP	ITS_1	4
Fata et al. (124)	2017	Razavi Khorasan	85	63	22	PCR	kDNA	6
Akia et al. (125)	2017	Kermanshah	47	40	7	RFLP	ITS_1	4
Mirahmadi et al. (126)	2018	Sistan and Baluchestan	98	53	45	RFLP	Cyt b	5
Namazi et al. (127)	2018	Razavi Khorasan	153	153	0	Nested PCR	kDNA	4
Teimouri et al. (128)	2018	Iran	108	48	60	RFLP	ITS_1	4
Zahirmia et al. (129)	2018	Yazd	52	48	4	RFLP	ITS_1	5
Ghatee et al. (130)	2018	Kerman	26	0	26	RFLP	kDNA	4
Ghatee et al. (130)	2018	Fars	13	0	13	RFLP	kDNA	4
Saberi et al. (8)	2018	Ilam	62	62	0	RFLP	NAGT	4
Mousavi et al. (131)	2018	Ilam	200	200	0	PCR	kDNA	4
Ramezany et al. (132)	2018	Kerman	174	20	154	PCR	ITS_1	4
Askari et al. (133)	2018	Ilam	160	160	0	RFLP	ITS_1	5
Mirzaei et al. (134)	2018	Ilam	23	15	8	PCR	kDNA	5
Fata et al. (135)	2018	Razavi Khorasan	42	29	13	PCR	kDNA	6
Gholamian et al. (136)	2018	Yazd	88	88	0	Nested PCR	kDNA	4
Mohammadiha et al. (137)	2018	Iran	654	478	176	RFLP	ITS_1&2	5
Mirzapour et al. (138)	2019	Lorestan	100	16	84	RFLP	ITS_1	6
Razavinasab et al. (139)	2019	Kerman	50	0	50	HRM	7SL RNA	5
Mohammadpour et al. (140)	2019	Fars	100	86	14	Nested PCR	kDNA, Cyt b	5
Barazesh et al. (141)	2019	Fars	66	60	6	PCR	kDNA	4
Ghobakhloo et al. (142)	2019	Fars	161	161	0	PCR	GAPDH	4
Mirahmadi et al. (143)	2019	Sistan and Baluchestan	111	68	43	RFLP	kDNA	5

(Continued)

TABLE 1 | Continued

References	Years	Province	Number samples	Species		PCR type	Used genetic marker	NOS score
				<i>L. major</i>	<i>L. tropica</i>			
Ziaei Hezarjaribi et al. (144)	2019	Kerman	40	0	40	PCR	kDNA	4
Zarezadeh et al. (145)	2019	Sistan and Baluchestan	82	36	46	RFLP	ITS_1, rDNA	5

(Several province) <sup>a</sup>Fars (n = 32), Kerman (n = 20), Tehran (n = 8), Isfahan (n = 7), Khuzestan (n = 4), Golestan (n = 2), and Yazd (n = 2).

(Several province) <sup>b</sup>Isfahan (n = 40), Ilam (n = 9), Razavi Khorasan (n = 7), Semnan (n = 6), and Khuzestan (n = 5).

(Several province) <sup>c</sup>Isfahan (n = 11), Khuzestan (n = 6), Semnan (n = 4), Ilam (n = 2), and Tehran (n = 1).

(Several province) <sup>d</sup>Isfahan (n = 59), Hormozgan (n = 47), Semnan (n = 43), Ilam (n = 42), Razavi Khorasan (n = 41), Fars (n = 30), Kerman (n = 21), Khuzestan (n = 21), Yazd (n = 20) Golestan (n = 13), and North Khorasan (n = 4).

(Several province) <sup>e</sup>Isfahan (n = 40), Razavi Khorasan (n = 15), Kermanshah (n = 11), Kerman (n = 9), Khuzestan (n = 1), Tehran (n = 1).

(Several province) <sup>f</sup>Isfahan (n = 4), Razavi Khorasan (n = 4), Fars (n = 4), Ilam (n = 3), Kerman (n = 2), Golestan (n = 2), Tehran (n = 1), Kermanshah (n = 1), Ardabil (n = 1), Hormozgan (n = 1), and Sistan and Baluchestan (n = 1).


TABLE 2 | Baseline characteristics of the *Leishmania* species identification from the VL cases in the systematic review and meta-analysis from 2005 to 2019.

References	Year	Province	Positive samples	Species		PCR type	Used genetic marker	NOS score
				<i>L. infantum</i>	<i>L. tropica</i>			
Sarkari et al. (146)	2005	Kohgiluyeh and Boyer Ahmad	6	6	0	Semi Nested	kDNA	3
Alborzi et al. (147)	2006	Fars	64	63	1	PCR	kDNA	3
Motazedian et al. (148)	2008	Fars	29	29	0	PCR	kDNA	4
Alborzi et al. (149)	2008	Fars	95	95	0	PCR	kDNA	5
Fayzi et al. (150)	2009	East Azerbaijan	14	14	0	PCR	kDNA	4
Fakhar et al. (151)	2011	Kermanshah	9	9	0	PCR	kDNA	3
Fakhar et al. (152)	2011	Fars	16	16	0	PCR	kDNA	3
Hajjaran et al. (70)	2013	Iran	28	26	2	RFLP	ITS_1	5
Mohammadiha et al. (153)	2013	Ardabil	77	77	0	Real-time PCR	kDNA	4
Fakhar et al. (154)	2014	Golestan	13	13	0	PCR	kDNA	6
Hosseininiasab et al. (155)	2014	Kerman	10	9	1	Nested PCR	kDNA	4
Ghasemian et al. (156)	2016	Tehran	45	45	0	Nested PCR—RT PCR	kDNA	4
Sarkari et al. (157)	2016	Fars	1	0	1	RFLP	NAGT	4
Hajjaran et al. (109)	2016	Tehran	7	4	3	Semi Nested RT PCR	NAGT, ITS_1	5
Asfaram et al. (158)	2017	Ardabil	16	16	0	PCR	kDNA	5
Asfaram et al. (159)	2017	Golestan	6	6	0	PCR	kDNA	4
Asfaram et al. (159)	2017	Mazandaran	1	1	0	PCR	kDNA	4
Dalimi et al. (160)	2018	Ardabil	14	14	0	RFLP	ITS_1	6
Dalimi et al. (160)	2018	Fars	9	9	0	RFLP	ITS_1	6
Dalimi et al. (160)	2018	Bushehr	3	3	0	RFLP	ITS_1	6
Dalimi et al. (160)	2018	East Azerbaijan	2	2	0	RFLP	ITS_1	6
Dalimi et al. (160)	2018	Tehran	2	2	0	RFLP	ITS_1	6
Masoori et al. (161)	2018	Lorestan	16	16	0	PCR	kDNA	5
Layegh Gigloo et al. (162)	2018	Fars	8	8	0	PCR	ITS_2	4
Rezaei et al. (163)	2018	Fars	8	8	0	PCR	ITS_2	5
Mirzaei et al. (134)	2018	Ilam	14	14	0	PCR	kDNA	5
Ghatee et al. (164)	2018	Kohgiluyeh and Boyer Ahmad	29	25	4	RFLP	ITS_1	4

replaced the isoenzyme method, which is the standard method for determining the species and strain of the *Leishmania* parasite (176). Molecular techniques have the potential to be more sensitive and rapid. In addition to high sensitivity and specificity,

molecular methods can differentiate relapse from reinfection of disease (177).

Several DNA markers were used for DNA amplification of *Leishmania* spp. in the included articles, in which most kDNA




and ITS1 markers were used for the diagnosis of identification of species. Our finding showed that the kDNA-based PCR was the most sensitive diagnostic method for leishmaniasis and the ITS1-based PCR could be used as a sensitive/specific method to identify the *Leishmania* species. It is interesting to know that ITS1 is less sensitive compared to kDNA minicircles, because the copy number of rDNA (<200) is lower than the copy number of kDNA minicircles (tens of thousands). Therefore, it is more desirable to use specific primers for ITS regions and kDNA genes to diagnose the disease (103).

Phylogenetic analyses targeting the ITS1 gene are valuable and reliable tools in genetic analytical characterization of *Leishmania* parasite. This region is highly conserved among species (178). The ITS region as a target for differentiation of *Leishmania*

at species and strain level has been used in different studies (102, 105, 132). As a whole, it should be noted that apply of two genetic markers simultaneously could provide more data regarding genetic map of the *Leishmania* parasite particularly in an endemic focus.

Notwithstanding that the DNA-based methods have proven to be very efficient in the identification and distinguish of *Leishmania* species, these methods also have limitations. One of these limitations is the exquisite sensitivity of these methods, and consequently false-positive PCR (179). For resolving this problem, it is necessary to use positive and negative control in each experiment simultaneously. Furthermore, preventing PCR contamination requires that this method be performed in reference laboratories. The specificity of PCR is generally



**FIGURE 3 |** Map of distribution of *Leishmania* spp. causing of visceral leishmaniasis using molecular methods in different geographical areas of Iran.

**TABLE 3 |** The pooled frequency, heterogeneity, and publication bias of *Leishmania* species that causative VL and CL leishmaniasis.

Variable	Meta-analysis							
	Pooled frequency	Heterogeneity				Publication bias		
		$I^2$	df	Cochran Q	P-value	Egger bias	P-value	
CL	<i>L. major</i>	67.3% (95% CI: 59.51–74.67%)	9625.83	134	98.6%	<0.001	-2.75	0.363
	<i>L. tropica</i>	32.1% (95% CI: 24.72–39.87%)	9693.55	134	98.6%	<0.001	3.11	0.306
VL	<i>L. infantum</i>	97.1% (95% CI: 94.6–98.8%)	39.53	21	46.9%	0.008	-0.81	0.016
	<i>L. tropica</i>	2.9% (95% CI: 1.12–5.37%)	39.53	21	46.9%	0.008	0.8175	0.016

controlled by several variables, including primer design, target genes, amount and purity of DNA, and type of enzyme (180).

In the end, the issue of the *Leishmania* RNA virus has become an interesting topic (181). *Leishmania* RNA virus (or LRV) is a genus of double-stranded RNA (dsRNA) virus in the family Totiviridae. LRVs exist within many species of the *Leishmania* isolates (181). Nowadays, *Leishmania* RNA virus is

being extensively surveyed because it might be an important virulence factor of the infection (182). According to previous evidence, studies have been conducted to investigate the presence of *Leishmania* RNA virus in Iran. It is interesting to know that *Leishmania* RNA virus has been detected in many *L. major* species and one *L. infantum* isolated from a VL patient, and one *L. tropica* isolated from a CL patient in Iran (110, 183).

## LIMITATIONS

One of the limitations of this study was that some authors did not report isolates to belong to which province and isolates were introduced to as Iranian isolates. In addition, the limitations of the present study include: (a) use of different diagnostic techniques in the two included studies without similar results, (b) available studies with no sufficient information on identification of *Leishmania* species, and (c) variability of the sample size of the included studies. Also, people commuting between urban and rural areas has made it difficult to determine the main source of infection.

## CONCLUSION

Our study reconfirms that CL and VL remain important infectious diseases in Iran. In this regard, the main causative agent of ZCL and ACL in Iran is *L. major* and *L. tropica*, respectively. In addition, the findings of this study demonstrated that the main causative agent of VL in Iran is *L. infantum*. The current study provides the geographical distribution of causative species in CL and VL forms in Iran and is a source of data to help researchers and public health workers in comprehensive investigations and developing prevention programs. Based on current findings, two markers kDNA and ITS1 can be used to accurately diagnose and determine *Leishmania* species using molecular methods. Our findings highlight the need for the implementation of control measures among the patients of both CL and VL. Further attention and monitoring will be needed

to improve the surveillance and effective control to reduce the incidence of leishmaniasis in Iran.

## DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/**Supplementary Material**, further inquiries can be directed to the corresponding author/s.

## AUTHOR CONTRIBUTIONS

HH and RS conceived the presented idea and wrote the manuscript. MF and MM reviewed and commented on the findings of this work. HH, AB, and SG initially searched the literature studies and collected the data. SH analyzed and interpreted the data and methods. All authors provided critical feedback and agreed to the published version of the manuscript.

## ACKNOWLEDGMENTS

We would like to express their thankfulness to all authors that their valuable publications were included in the current review.

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fpubh.2021.661674/full#supplementary-material>

## REFERENCES

- Tamir HF, Mashalla YJ, Mohammed R, Tshweneagae GT. Cutaneous leishmaniasis a neglected tropical disease: community knowledge, attitude and practices in an endemic area, Northwest Ethiopia. *BMC Infect Dis.* (2019) 19:855. doi: 10.1186/s12879-019-4506-1
- Desjeux P. Leishmaniasis: current situation and new perspectives. *Comp Immunol Microb Infect Dis.* (2004) 27:305–18. doi: 10.1016/j.cimid.2004.03.004
- McIlwee BE, Weis SE, Hosler GA. Incidence of endemic human cutaneous leishmaniasis in the United States. *JAMA Dermat.* (2018) 154:1032–9. doi: 10.1001/jamadermatol.2018.2133
- Ruiz-Postigo JA, Grout L, Saurabh J. Global leishmaniasis surveillance, 2017–2018, and first report on 5 additional indicators/Surveillance mondiale de la leishmaniose, 2017–2018, et premier rapport sur 5 indicateurs supplémentaires. *Weekly Epidemiol Record.* (2020) 95:265–80. Available online at: <https://reliefweb.int/report/world/weekly-epidemiological-record-wer-19-june-2020-vol-95-25-pp-265-280-enfr>
- Al-Salem W, Herricks JR, Hotez PJ. A review of visceral leishmaniasis during the conflict in South Sudan and the consequences for East African countries. *Paras Vect.* (2016) 9:460. doi: 10.1186/s13071-016-1743-7
- Holakouie-Naieni K, Mostafavi E, Bolorani AD, Mohebbali M, Pakzad R. Spatial modeling of cutaneous leishmaniasis in Iran from 1983 to (2013). *Acta Tropica.* (2017) 166:67–73. doi: 10.1016/j.actatropica.2016.11.004
- Sharifi I, Aflatoonian MR, Parizi MHD, Hosseiniinasab A, Mostafavi M, Bamorovat M, et al. Visceral leishmaniasis in Southeastern Iran: a narrative review. *Iran J Parasit.* (2017) 12:1–11.
- Saber R, Moin-Vaziri V, Hajjaran H, Niyati M, Taghipour N, Kheirandish F, et al. Identification of *Leishmania* species using N-acetylglucosamine-1-phosphate transferase gene in a zoonotic cutaneous leishmaniasis focus of Iran. *J Vect Borne Dis.* (2018) 55:14. doi: 10.4103/0972-9062.234621
- Hajjaran H, Mohebbali M, Teimouri A, Oshaghi MA, Mirjalali H, Kazemi-Rad E, et al. Identification and phylogenetic relationship of Iranian strains of various *Leishmania* species isolated from cutaneous and visceral cases of leishmaniasis based on N-acetylglucosamine-1-phosphate transferase gene. *Infect Genet Evolu.* (2014) 26:203–12. doi: 10.1016/j.meegid.2014.05.026
- Akhoundi M, Downing T, Votýpka J, Kuhls K, Lukeš J, Cannet A, et al. *Leishmania* infections: molecular targets and diagnosis. *Mol Aspects Med.* (2017) 57:1–29. doi: 10.1016/j.mam.2016.11.012
- Moher D, Liberati A, Tetzlaff J, Altman D. Academia and clinic annals of internal medicine preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Annu Intern Med* 151:264–269. (2009) doi: 10.7326/0003-4819-151-4-200908180-00135
- Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Europ J Epidemiol.* (2010) 25:603–5. doi: 10.1007/s10654-010-9491-z
- Alimohammadian MH, Almasi H, Khabiri A, Hatam G, Mahboudi F, Tehrani SR, et al. Identification of species and characteristics of an outbreak of cutaneous leishmaniasis in a new focus of Iran. *Iran Biomed J.* (1999) 3:31–9. Available online at: <http://ibj.pasteur.ac.ir/article-1-847-en.html>
- Motazedian H, Noamanpoor B, Ardehali S. Characterization of *Leishmania* parasites isolated from provinces of the Islamic Republic of Iran. *EMHJ-Eastern Med Health J.* (2002) 8:338–44.
- Tashakori M, Azhdari S, Kariminia A, Ali MM, Mahboudi F. Characterization of *Leishmania* species and *L. major* strains in different endemic areas of cutaneous leishmaniasis in Iran. *IBG.* (2003) 7:43–50. Available online at: <http://ibj.pasteur.ac.ir/article-1-537-en.html>
- Hajjaran H, Mohebbali M, Razavi M, Mojtavavi J, Houshmand B. Identification of *Leishmania* species isolated from human cutaneous

- leishmaniasis, using random amplified polymorphic DNA (RAPD-PCR). *Iran. J. Public Health.* (2004) 33:8–15. Available online at: <https://www.sid.ir/en/journal/ViewPaper.aspx?ID=13302>
17. Motazedian M, Karamian M, Ardehali S, Handjani F. Characterization of *Leishmania* parasites from archived Giemsa-stained slides using nested polymerase chain reaction. *JMR.* (2004) 33:8–15. Available online at: <https://www.sid.ir/en/Journal/ViewPaper.aspx?ID=48462>
  18. Hadighi R, Mohebalı M, Boucher P, Hajjaran H, Khamesipour A, Ouellette M. Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant *Leishmania tropica* parasites. *PLoS MED.* (2006) 3:e162. doi: 10.1371/journal.pmed.0030162
  19. Mahnaz T, Katrin K, Amer A-J, Isabel M, Gabriele S, Safar F, et al. *Leishmania major*: genetic heterogeneity of Iranian isolates by single-strand conformation polymorphism and sequence analysis of ribosomal DNA internal transcribed spacer. *Acta Tropica.* (2006) 98:52–8. doi: 10.1016/j.actatropica.2006.01.010
  20. Akhavan A, Yaghoobi-Ershadi M, Hasibi F, Jafari R, Abdoli H, Arandian M, et al. Emergence of cutaneous leishmaniasis due to *Leishmania major* in a new focus of southern Iran. *J Arthrop Born Dis.* (2007) 1–8. Available online at: <https://jad.tums.ac.ir/index.php/jad/article/view/3>
  21. Maraghi S, Zadeh AS, Sarlak A, Ghasemian M, Vazirianzadeh B. Identification of cutaneous leishmaniasis agents by nested Po-Lymerase chain reaction (Nested-PCR) in Shush City, Khuzestan Province, Iran. *Iran J Parasit.* (2007) 13–5. Available online at: <https://ijpa.tums.ac.ir/index.php/ijpa/article/view/29>
  22. Kazemi-Rad E, Mohebalı M, Hajjaran H, Rezaei S, Mamishi S. Diagnosis and characterization of *Leishmania* species in Giemsa-stained slides by PCR-RFLP. *Iran J Public Health.* (2008) 54–60. Available online at: <https://ijph.tums.ac.ir/index.php/ijph/article/view/2073>
  23. Shahbazi F, Shahabi S, Kazemi B, Mohebalı M, Abadi AR, Zare Z. Evaluation of PCR assay in diagnosis and identification of cutaneous leishmaniasis: a comparison with the parasitological methods. *Parasit Res.* (2008) 103:1159–62. doi: 10.1007/s00436-008-1111-4
  24. Fazaeli A, Fouladi B, Hashemi SS, Sharifi I. Clinical features of cutaneous leishmaniasis and direct pcrbased identification of parasite species in a new focus in Southeast of Iran. *Iran J Public Health.* (2008) 37:44–51. Available online at: <https://www.sid.ir/en/journal/ViewPaper.aspx?id=117574>
  25. Mohajery M, Hajjaran H, Shamsiyan AA, Tavakkol Afshari J, Saadabadi F. Identification of *Leishmania* Species Causing Cutaneous Leishmaniasis by RAPD-PCR. *Med J Mashhad Univers Med Sci.* (2008) 51:79–86. Available online at: <http://eprints.mums.ac.ir/id/eprint/7716>
  26. Alimoradi S, Hajarani H, Mohebalı M, Mansouri F. Molecular identification of *Leishmania* species isolated from human cutaneous leishmaniasis by RAPD-PCR. *Iranian J Publ Health.* (2009) 38:44–50. Available online at: <https://ijph.tums.ac.ir/index.php/ijph/article/view/3188>
  27. Rahbarian N, Mesgarian A, Mahmoudirad M, Hajarani H, Shahbazi F, Mesgarian Z, et al. Identification of *Leishmania* species isolated from human cutaneous leishmaniasis using PCR method. *J Res Health Sci.* (2009) 9:48–51.
  28. Razmjou S, Hejazy H, Motazedian MH, Baghaei M, Emamy M, Kalantary M. A new focus of zoonotic cutaneous leishmaniasis in Shiraz, Iran. *Trans R Soc Trop Med Hygiene.* (2009) 103:727–30. doi: 10.1016/j.trstmh.2008.12.013
  29. Emami MM, Yazdi M, Nilforoushzadeh M. Emergence of cutaneous leishmaniasis due to *Leishmania major* in a new focus of central Iran. *Trans R Soc Trop Med Hygiene.* (2009) 103:1257–62. doi: 10.1016/j.trstmh.2009.04.020
  30. Fazaeli A, Fouladi B, Sharifi I. Emergence of cutaneous leishmaniasis in a border area at south-east of Iran: an epidemiological survey. *J Vect Borne Dis.* (2009) 46:36.
  31. Khalili M, Nourollahi-Fard S. Detection and genotyping of cutaneous leishmaniasis species in the southeast of Iran: restriction enzyme analysis (RFLP). *Tehran Univer Med J.* (2009) 67:168–72. Available online at: <https://tumj.tums.ac.ir/article-1-466-en.pdf>
  32. Pirstani M, Sadraei J, Dalimi A, Vaeznia, H. Determination of *Leishmania* species causing cutaneous leishmaniasis in Mashhad by PCR-RFLP method. *Arch Razi Instit.* (2009) 64:39–44. doi: 10.22092/ARI.2009.103804
  33. Sharifi I, Fekri AR, Aflatoonian MR, Khamesipour A, Mahboudi F, Dowlati Y, et al. Leishmaniasis recidivans among school children in Bam, South-east Iran, 1994–2006. *Int J Dermat.* (2010) 49:557–61. doi: 10.1111/j.1365-4632.2010.04419.x
  34. Doudi M, Hejazi SH, Razavi MR, Narimani M, Khanjani S, Eslami G. Comparative molecular epidemiology of *Leishmania major* and *Leishmania tropica* by PCR-RFLP technique in hyper endemic cities of Isfahan and Bam, Iran. *Med Sci Monitor.* (2010) 16:CR530-CR5.
  35. Saki J, Meamar A, Oormazdi H, Akhlaghi L, Maraghi S, Mohebalı M, et al. Mini-exon genotyping of leishmania species in khuzestan province, southwest Iran. *Iran J Parasit.* (2010) 5:25.
  36. Pourmohammadi B, Motazedian M, Hatam G, Kalantari M, Habibi P, Sarkari B. Comparison of three methods for diagnosis of cutaneous leishmaniasis. *Iran J Parasit.* (2010) 5:1–8.
  37. Mahmoudi MR, Mohajeri M, Tavakol AJ, Shakeri MT, Yazdanpanah MJ, Berenji F, et al. Molecular identification of *Leishmania* species causing cutaneous leishmaniasis in Mashhad, Iran. *IJM.* (2010) 3:195–200. Available online at: <https://sites.kowsarpub.com/ijm/articles/72551.html>
  38. Mesgarian F, Rahbarian N, Mahmoudi Rad M, Hajarani H, Shahbaz F, Mesgarian Z, et al. Identification of *Leishmania* species isolated from human cutaneous Leishmaniasis in Gonbad-e-Qabus city using a PCR method during 2006–2007. *Tehran Univ Med J.* (2010) 68:250–6. Available online at: <http://tumj.tums.ac.ir/article-1-355-en.html>
  39. Mohajery M, Shamsian SA, Rezaei A, Hasan Poor K, Shakeri MT, Farnoosh G, et al. Evaluation of molecular epidemiology of cutaneous leishmaniasis in Sabzevar. *Med J Mashhad Univers Med Sci.* (2010) 53:138–44. doi: 10.22038/mjms.2010.5376
  40. Fakhari M, Mikaeili F, Hatam G, Habibi P, Karamian M, Motazedian M, et al. A molecular epidemiology survey of cutaneous Leishmaniasis in patients referring to Parasitology Lab at Shiraz School of Medicine and the importance of PCR assay. *J Jahrom Univer Med Sci.* (2010) 8:2–6. doi: 10.29252/jmj.8.1.2
  41. Hamzavi Y, Nomanpour B, Karaji AG. Identification of species of *Leishmania* isolated from patients with cutaneous leishmaniasis in Kermanshah; using RAPD-PCR technique. *J Kermanshah Univ Med Sci.* (2010) 14:167–270. Available online at: <https://sites.kowsarpub.com/jkums/articles/79482.html>
  42. Ghasemian M, Maraghi S, Samarbafzadeh A, Jelowdar A, Kalantari M. The PCR-based detection and identification of the parasites causing human cutaneous leishmaniasis in the Iranian city of Ahvaz. *Ann Trop Med Parasit.* (2011) 105:209–15. doi: 10.1179/136485911X12899838683520
  43. Farahmand M, Nahrevanian H, Shirazi HA, Naeimi S, Farzanehnejad Z. An overview of a diagnostic and epidemiologic reappraisal of cutaneous leishmaniasis in Iran. *Brazil J Infect Dis.* (2011) 15:17–21. doi: 10.1590/S1413-86702011000100004
  44. Hajjaran H, Vasigheh F, Mohebalı M, Rezaei S, Mamishi S, Charedar S. Direct diagnosis of *Leishmania* species on serosity materials punctured from cutaneous leishmaniasis patients using PCR-RFLP. *J Clin Lab Analysis.* (2011) 25:20–4. doi: 10.1002/jcla.20377
  45. Sharifi I, Poursmaeliani S, Aflatoonian MR, Ardakani RF, Mirzaei M, Fekri AR, et al. Emergence of a new focus of anthroponotic cutaneous leishmaniasis due to *Leishmania tropica* in rural communities of Bam district after the earthquake, Iran. *Trop Med Int Health.* (2011) 16:510–3. doi: 10.1111/j.1365-3156.2011.02729.x
  46. Sharifi I, Nakhaei N, Aflatoonian M, Parizi MH, Fekri A, Safizadeh H, et al. Cutaneous leishmaniasis in Bam: a comparative evaluation of pre-and post-earthquake years (1999–2008). *Iran J Public Health.* (2011) 40:49–56.
  47. Khademvatan S, Neisi N, Maraghi S, Saki J. Diagnosis and identification of *Leishmania* spp. from Giemsa-stained slides, by real-time PCR and melting curve analysis in south-west of Iran. *Ann Trop Med Parasit.* (2011) 105:559–65. doi: 10.1179/2047773211Y.0000000014
  48. Mohammadi Azni S, Rasi Y, Oshaghi MA, Yaghoobi Ershadi M, Mohebalı M, Abaie M, et al. Diagnosis and characterization of leishmania species in patients and rodents Giemsa-stained slides by PCR-RFLP in Damghan district, Iran. *Avicenna J Clin Med.* (2011) 17:5–9. Available online at: <http://sjh.umsha.ac.ir/article-1-250-en.html>
  49. Pour R, Sharifi I, Kazemi B, Zarean M. Identification of nonresponsive isolates to Glucantime in patients with cutaneous Leishmaniasis in Bam. *J Kerman Univer Med Sci.* (2011) 18:123–34. Available online at: <https://www.sid.ir/en/journal/ViewPaper.aspx?ID=191002>
  50. Mohammadi Azni S, Rasi Y, Oshaghi MA, Yaghoobi Ershadi MR, Mohebalı M, Abai MR, et al. Determination of parasite species of cutaneous leishmaniasis using Nested PCR in Damghan – Iran, during 2008. *J Gorgan Uni Med Sci.* (2010) 1359–65. Available online at: <https://www.sid.ir/en/journal/ViewPaper.aspx?id=258744>

51. Poresmaeliani S, Mirzaei M, SHarifi E, Zarean M. The prevalence of cutaneous leishmaniasis in the city and suburb of Mohammadabad, Jiroft district and identification of parasite species by Nested-PCR, 2008. *J Kerman Univer Med Sci.* (2011) 18:218–27. Available online at: [http://jkmu.kmu.ac.ir/article\\_16565.html](http://jkmu.kmu.ac.ir/article_16565.html)
52. Azizi K, Soltani A, Alipour H. Molecular detection of *Leishmania* isolated from cutaneous leishmaniasis patients in Jask County, Hormozgan Province, Southern Iran, 2008. *Asian Pacific J Trop Med.* (2012) 5:514–7. doi: 10.1016/S1995-7645(12)60090-X
53. Khosravi S, Hejazi H, Hashemzadeh-Chaleshtori M, Eslami G, Yousofi Darani H. Molecular diagnosis of Old World leishmaniasis: real-time PCR based on trypanredoxin peroxidase gene for the detection and identification of *Leishmania* spp. *J Vect Borne Dis.* (2012) 49:15–8.
54. Sharifi F, Sharifi I, Zarean M, Parizi MH, Aflatoonian M, Harandi MF, et al. Spatial distribution and molecular identification of *Leishmania* species from endemic foci of south-eastern Iran. *Iran J Parasit.* (2012) 7:45–52.
55. Mahmoudzadeh-Niknam H, Ajdary S, Riazi-Rad F, Mirzadegan E, Rezaeian A, Khazaei V, et al. Molecular epidemiology of cutaneous leishmaniasis and heterogeneity of *Leishmania major* strains in Iran. *Trop Med Int Health.* (2012) 17:1335–44. doi: 10.1111/j.1365-3156.2012.03078.x
56. Shiee MR, Mohebbali M, Doroodgar A, Teimouri A, Afzali H, Shirzadi MR. A molecular and parasitological survey on cutaneous leishmaniasis patients from historical city of Kashan in Isfahan province, center of Iran. *Asian Pacific Journal of Tropical Disease.* (2012) 2:421–5. doi: 10.1016/S2222-1808(12)60093-0
57. Hashemi N, Hashemi M, Eslami G, Bidabadi LS, Hejazi SH. Detection of *Leishmania* parasites from cutaneous Leishmaniasis patients with negative direct microscopy using NNN and PCR-RFLP. *J Isfahan Med School.* (2012) 29:169. Available online at: <http://jims.mui.ac.ir/index.php/jims>
58. Mirzaei M, Sharifi I, Poursmaeliani S. A new focus of anthroponotic cutaneous leishmaniasis and identification of parasite species by nested PCR in Jiroft, Iran. *Comp Clin Pathol.* (2012) 21:1071–5. doi: 10.1007/s00580-011-1231-6
59. Mohammadi F, Narimani M, Nekoian S, Bidabadi LS, Mohammadi F, Hosseini SM, et al. Identification and isolation of the cause of cutaneous Leishmaniasis in Isfahan Using ITS-PCR method. *J Isfahan Med School.* (2012) 30:175.
60. Saghafipour A, Rassi Y, Abai MR, Oshaghi Ma, Yaghoobi Arshadi Mr, Mohebbali M, et al. Identification of *Leishmania* species in patients and reservoir rodents using PCR-RFLP in the central county of Qom province in 2010. *J Arak Univer Med Sci.* (2012) 15:1–10. Available online at: <http://jams.arakmu.ac.ir/article-1-1249-en.html>
61. Baghaei A, Jasbi E, Akhouni M, Mirzaei H, Dehnam O. Microscopic and molecular detection of *Leishmania* species among suspected patients of cutaneous leishmaniasis using ITS-r DNA in Fars Province. *SSU Journals.* (2012) 20:464–73. Available online at: <http://jssu.ssu.ac.ir/article-1-2136-en.html>
62. Baghaei A, Parvizi P, Amirkhani A, Honarvar M, Badiie F. Identification of *Leishmania* using microscopic and molecular methods in suspected patients of Cutaneous Leishmaniasis by targeting ITS-rDNA gene, Golestan province, Iran (2009–10). *J Gorgan Uni Med Sci.* (2012) 14:72–81. Available online at: <https://www.sid.ir/en/journal/ViewPaper.aspx?ID=274014>
63. Kazemi-Rad E, Mohebbali M, Khadem-Erfan MB, Saffari M, Raoofian R, Hajjaran H, et al. Identification of antimony resistance markers in *Leishmania tropica* field isolates through a cDNA-AFLP approach. *Exp Parasitol.* (2013) 135:344–9. doi: 10.1016/j.exppara.2013.07.018
64. Akhouni M, Hajjaran H, Baghaei A, Mohebbali M. Geographical distribution of *Leishmania* species of human cutaneous leishmaniasis in Fars province, southern Iran. *Iran J Parasit.* (2013) 8:85.
65. Maraghi S, Mardanshah O, Rafei A, Samarbazfzadeh A, Vazirianzadeh B. Identification of cutaneous leishmaniasis agents in four geographical regions of Khuzestan province using Nested PCR. *Jundishapur J Microbiol.* (2013) 6:1–4. doi: 10.5812/jjm.4866
66. Kheirandish F, Sharafi AC, Kazemi B, Mohebbali M, Sarlak A, Tarahi MJ, et al. Identification of *Leishmania* species using PCR assay on giemsa-stained slides prepared from cutaneous leishmaniasis patients. *Iran J Parasit.* (2013) 8:382.
67. Yaghoobi-Ershadi MR, Shahbazi F, Darvishi M, Akhavan AA, Jafari R, Khajeian M, et al. Molecular epidemiological study of cutaneous leishmaniasis in the focus of Bushehr city, southwestern Iran. *J Arthropod-Borne Dis.* (2013) 7:113.
68. Kheirandish F, Sharafi AC, Kazemi B, Bandehpour M, javad Tarahi M, Khamesipour A. First molecular identification of *Leishmania* species in a new endemic area of cutaneous leishmaniasis in Lorestan, Iran. *Asian Pacific J Trop Med.* (2013) 6:713–7. doi: 10.1016/S1995-7645(13)60124-8
69. Saadabadi F, Mohajery M, Poostchi E, Shamsian SAA. Identification of *Leishmania* species causing cutaneous leishmaniasis using Random Amplified Polymorphic DNA (RAPD-PCR) in Kharve, Iran. *Rep Biochem Mol Biol.* (2013) 1:69.
70. Hajjaran H, Mohebbali M, Mamishi S, Vasigheh F, Oshaghi MA, Naddaf SR, et al. Molecular identification and polymorphism determination of cutaneous and visceral leishmaniasis agents isolated from human and animal hosts in Iran. *BioMed Res Int.* (2013) 2013:326. doi: 10.1155/2013/789326
71. Oryan A, Shirian S, Tabandeh M-R, Hatam G-R, Randau G, Daneshbod Y. Genetic diversity of *Leishmania major* strains isolated from different clinical forms of cutaneous leishmaniasis in southern Iran based on minicircle kDNA. *Infect Genet Evol.* (2013) 19:226–31. doi: 10.1016/j.meegid.2013.07.021
72. Aflatoonian MR, Sharifi I, Poursmaeliani S, Hakimi-Parizi M, Ziaali N. The emergence of anthroponotic cutaneous leishmaniasis following the earthquake in southern villages of Bam district, southeastern Iran, 2010. *J Arthro Borne Dis.* (2013) 7:8.
73. Taghizadeh N, Jafari M, Borjian Boroujeni A, Hejazi S, Azizi H. Detection and identification of *Leishmania* isolates from patients with cutaneous leishmaniasis (CL) in Isfahan (central region of Iran) by PCR method. *Arch Razi Instit.* (2013) 68:153–8. doi: 10.7508/ari.2013.02.010
74. Badirzadeh A, Mohebbali M, Ghasemian M, Amini H, Zarei Z, Akhouni B, et al. Cutaneous and post kala-azar dermal leishmaniasis caused by *Leishmania infantum* in endemic areas of visceral leishmaniasis, northwestern Iran 2002–2011: a case series. *Pathog Global Health.* (2013) 107:194–7. doi: 10.1179/2047773213Y.0000000097
75. Farash BRH, Mohajery M, Fata A, Shamsian SA, Rezaee A, Yazdanpanah MJ. Anthroponotic cutaneous leishmaniasis in torghabeh-shandiz, a region with rural texture (a molecular study). *Jundishapur J Microbiol.* (2013) 6:e8274. doi: 10.5812/jjm.8274
76. Mohammadi AMA, Khamesipour A, Khatami A, Javadi A, Nassiri-Kashani M, Firooz A, et al. Cutaneous leishmaniasis in suspected patients referred to the center for research and training in skin diseases and leprosy, Tehran, Iran from 2008 to 2011. *Iran J Parasitol.* (2013) 8:430.
77. Beiranvand E, Kalantari M, Rastgar HA, Amraee K. Molecular identification of *Leishmania* species isolated from human cutaneous leishmaniasis in Poledokhtar District, Lorestan Province, Iran. *Jundishapur J Microbiol.* (2013) 6:e8103. doi: 10.5812/jjm.8103
78. Karamian M, Faroghi Bojd MS, Hemmati M, Saadatjoo A, Barati DA. Molecular identification of cutaneous leishmaniasis agents in Birjand, Iran. *J Birjand Univer Med Sci.* (2013) 20:183–90. Available online at: <http://journal.bums.ac.ir/article-1-1378-en.html>
79. Pagheh AS, Fakhar M, Mesgarian F, Rahimi-Esboei B, Badiie F. Incidence trend of rural cutaneous leishmaniasis in Gonbad-e-Qabus city, (Golestan, Iran) during 2009–2012. *J Mazandaran Univ Med Sci.* (2013) 23:27–33. Available online at: <http://jmmums.mazums.ac.ir/article-1-2627-en.html>
80. Mirzaei F, Eslami G, Yosefi MH, Pestehchian N. Molecular identification of *Leishmania* isolates obtained from patients suspected as having cutaneous leishmaniasis referred to reference laboratories from Yazd province in central Iran. *Adv Biomed Res.* (2013) 2:92. doi: 10.4103/2277-9175.122525
81. Spotin A, Rouhani S, Parvizi P. The associations of *Leishmania major* and *Leishmania tropica* aspects by focusing their morphological and molecular features on clinical appearances in Khuzestan Province, Iran. *Biomed Res Int.* (2014) 2014:913510. doi: 10.1155/2014/913510
82. Tolouei S, Hejazi SH, Ghaedi K, Hashemina SJ. Identification of *Leishmania* isolates from healing and nonhealing cutaneous leishmaniasis patients using internal transcribed spacer region PCR. *Jundishapur J Microbiol.* (2014) 7:e9529. doi: 10.5812/jjm.9529
83. Shirian S, Oryan A, Hatam G-R, Panahi S, Daneshbod Y. Comparison of conventional, molecular, and immunohistochemical methods in diagnosis of typical and atypical cutaneous leishmaniasis. *Arch Pathol Lab Med.* (2014) 138:235–40. doi: 10.5858/arpa.2013-0098-OA
84. Salehi Gh, Fata A, Mohaghegh MA, Mousavi SM, Rafatpanah H, Movahedi A. Molecular identification of *Leishmania* species in

- Taybad district, Iran. *Asian Pacific J Trop Dis.* (2014) 4 (2):S535–S539. doi: 10.1016/S2222-1808(14)60672-1
85. Eslami G, Hajjimoammadi B, Jafari AA, Mirzaei F, Gholamrezaei M, Anvari H, et al. Molecular identification of *Leishmania tropica* infections in patients with cutaneous leishmaniasis from an endemic central of Iran. *Trop Biomed.* (2014) 31:592–9.
  86. Arjmand R, Saberi S, Tolouei S, Chizari Z, Nobari RF, Fard SS, et al. Identification of *Leishmania* isolates from Varzaneh city, Isfahan province, Iran using nested polymerase chain reaction method. *Adv Biomed Res.* (2014) 3:131. doi: 10.4103/2277-9175.139131
  87. Hassanpour K, Aghamollaei H, Golpich M, Amani J, Taheri A, Farnoosh G. Molecular epidemiological study of cutaneous leishmaniasis in the east north of Iran. *Asian Pacific J Trop Dis.* (2014) 4:S540–S4. doi: 10.1016/S2222-1808(14)60673-3
  88. Ghatee MA, Sharifi I, Kuhls K, Kanannejad Z, Harandi MF, de Almeida ME, et al. Heterogeneity of the internal transcribed spacer region in *Leishmania tropica* isolates from southern Iran. *Exp Paras.* (2014) 144:44–51. doi: 10.1016/j.exppara.2014.06.003
  89. Bordbar A, Parvizi P. High density of *Leishmania* major and rarity of other mammals' *Leishmania* in zoonotic cutaneous leishmaniasis foci, Iran. *Trop Med Int Health.* (2014) 19:355–63. doi: 10.1111/tmi.12258
  90. Moravvej H, Vesal P, Abolhasani E, Nahidi S, Mahboudi F. Comorbidity of *Leishmania major* with cutaneous sarcoidosis. *Indian J Dermatol.* (2014) 59:316. doi: 10.4103/0019-5154.131453
  91. Karimian Shirazi M, Razmi G, Naghibi A. Molecular Identification of *Leishmania* species causing cutaneous Leishmaniasis In Mashhad area, Iran. *J Birjand Univers Med Sci.* (2014) 21:237–45. Available online at: <http://journal.bums.ac.ir/article-1-1473-en.html>
  92. Abdolmajid F, Ghodrattollah SS, Hushang R, Mojtaba MB, Ali MM, Abdolghayoum M. Identification of *Leishmania* species by kinetoplast DNA-polymerase chain reaction for the first time in Khaf district, Khorasan-e-Razavi province, Iran. *Trop Parasitol.* (2015) 5:50–4. doi: 10.4103/2229-5070.145587
  93. Shamsian S, Rezaei A, Akbarzadeh A, Hosseini Farash B. Molecular Identification of *Leishmania tropica* in an endemic border city for zoonotic cutaneous leishmaniasis (ZCL) in northeastern Iran. *J Microb Exp.* (2015) 2:53–8. doi: 10.15406/jmen.2015.02.00053
  94. Spotin A, Rouhani S, Ghaemmaghami P, Haghighi A, Zolfaghari MR, Amirkhani A, et al. Different morphologies of *Leishmania major* amastigotes with no molecular diversity in a neglected endemic area of zoonotic cutaneous leishmaniasis in Iran. *Iran Biomed J.* (2015) 19:149–59. doi: 10.7508/ibj.2015.03.004
  95. Mohebbali M, Darabi H, Hajjaran H, Shirzadi MR, Fouladvand M, Charehdar S, et al. Molecular and parasitological study of cutaneous leishmaniasis in Bushehr province, southwest of the Islamic Republic of Iran: a cross-sectional study during 2009–2012. *J Parasit Dis.* (2015) 39:371–6. doi: 10.1007/s12639-013-0370-x
  96. Doroodgar A, Sadr F, Razavi MR, Doroodgar M, Asmar M, Doroodgar M. A new focus of zoonotic cutaneous leishmaniasis in Isfahan Province, Central Iran. *Asian Pacific J Trop Dis.* (2015) 5(Suppl. 1):S54–S8. doi: 10.1016/S2222-1808(15)60857-X
  97. Kolivand M, Fallah M, Salehzadeh A, Davari B, Poormohammadi A, Pazoki Ghohe H, et al. An epidemiological study of cutaneous leishmaniasis using active case finding among elementary school students in Pakdasht, Southeast of Tehran, Iran 2013–2014. *J Res Health Sci.* (2015) 15:104–8.
  98. Gholami-Parizad E, Maleki Ravanan N, Gholami-Parizad E, Karimian F, Karimian B. Frequency and molecular identification of leishmania parasites in smears prepared from skin lesions of patients referred to health centers of Ilam province by digestion of the rDNA-ITS1 gene. *Pathob Res.* (2015) 18:75–85. Available online at: <http://mjms.modares.ac.ir/article-30-2489-en.html>
  99. Hezari F, Niyayati M, Tabaei SJS, Mohebbali M, Vaziri VM, Behniafar H, et al. Frequency of cutaneous leishmaniasis and species identification in suspected individuals from Golestan province, Northern Iran in 2014. *Iran J Public Health.* (2016) 45:1348.
  100. Haddad MHE, Ghasemi E, Maraghi S, Tavalai M. Identification of *Leishmania* species isolated from human cutaneous leishmaniasis in Mehran, Western Iran using nested PCR. *Iran J Parasit.* (2016) 11:65.
  101. Naseri A, Fata A, Rezaei A, Hedayatimoghdam M, Berengi F, Akbarzadeh O, et al. Molecular identification of leishmania species in Torbat-e Heydarieh, Khorasan Razavi province, Iran. *Int J Med Res Health Sci.* (2016) 5:87–92.
  102. Ghasemloo H, Rasti S, Delavari M, Doroodgar A. Molecular diagnosis of clinical isolates of Cutaneous leishmaniasis using ITS1 and KDNA genes and genetic polymorphism of *Leishmania* in Kashan, Iran. *Pak J Biol Sci.* (2016) 19:136. doi: 10.3923/pjbs.2016.136.142
  103. Rasti S, Ghorbanzadeh B, Kheirandish F, Mousavi SG, Pirozmand A, Hooshyar H, et al. Comparison of molecular, microscopic, and culture methods for diagnosis of cutaneous leishmaniasis. *J Clin Lab Analysis.* (2016) 30:610–5. doi: 10.1002/jcla.21910
  104. Mirahmadi H, Khorashad AS, Sohrabnabad A, Heydarian P, Bizhani N. Species identification and molecular typing of *Leishmania* spp. using targeting HSP70 gene in suspected patients of cutaneous leishmaniasis from Sistan and Baluchestan Province, Southeast Iran. *Iran J Parasit.* (2016) 11:489.
  105. Dabirzadeh M, Hashemi M, Maroufi Y. Study of genetic variation of *Leishmania major* based on internal transcribed spacer 1 (ITS1) in Chabahar, Iran. *Jundish J Microb.* (2016) 9:33498. doi: 10.5812/jjm.33498
  106. Sharifi-Rad M, Dabirzadeh M, Sharifi I, Babaei Z. *Leishmania major*: genetic profiles of the parasites isolated from Chabahar, Southeastern Iran by PPIP-PCR. *Iran J Parasit.* (2016) 11:290.
  107. Sarkari B, Ahmadvand NB, Motazedian MH, Mirjalali H, Akhondji M, Mohebbali M, et al. Inter- and intraspecific variations of leishmania strains isolated from patients with cutaneous and visceral leishmaniasis in Fars Province, South of Iran. *Iran J Med Sci.* (2016) 41:209.
  108. Abedi-Astaneh F, Hajjaran H, Yaghoobi-Ershadi MR, Hanafi-Bojd AA, Mohebbali M, Shirzadi MR, et al. Risk mapping and situational analysis of cutaneous leishmaniasis in an endemic area of central Iran: A GIS-based survey. *PLoS ONE.* (2016) 11:e0161317. doi: 10.1371/journal.pone.0161317
  109. Hajjaran H, Mahdi M, Mohebbali M, Samimi-Rad K, Atefi-Pirkooch A, Kazemi-Rad E, et al. Detection and molecular identification of *Leishmania* RNA virus (LRV) in Iranian *Leishmania* species. *Arch Virol.* (2016) 161:3385–90. doi: 10.1007/s00705-016-3044-z
  110. Izadi S, Mirhendi H, Jalalvand N, Khodadadi H, Mohebbali M, Nekoeian S, et al. Molecular epidemiological survey of cutaneous leishmaniasis in two highly endemic metropolises of Iran, application of FTA cards for DNA extraction from Giemsa-stained slides. *Jundish J Microb.* (2016) 9:32885. doi: 10.5812/jjm.32885
  111. Karamian M, Kuhls K, Hemmati M, Ghatee MA. Phylogenetic structure of *Leishmania tropica* in the new endemic focus Birjand in East Iran in comparison to other Iranian endemic regions. *Acta Tropica.* (2016) 158:68–76. doi: 10.1016/j.actatropica.2016.02.010
  112. Mohammadpour I, Motazedian MH, Handjani F, Hatam GR. Cutaneous leishmaniasis of the eyelids: a case series with molecular identification and literature review. *Kor J Parasit.* (2016) 54:787. doi: 10.3347/kjp.2016.54.6.787
  113. Soltan SS, Spotin A, Ebrahimi S, Alaeevovin E, Bordbar A, Parvizi P. Various morphologic shapes of *Leishmania major* amastigotes with low genetic structure among people afflicted with zoonotic cutaneous leishmaniasis in khuzestan province. *IJIDTM.* (2016) 21:61–74. Available online at: <https://www.sid.ir/en/Journal/ViewPaper.aspx?ID=524027>
  114. Pazoki Ghohe H, Pagheh AS, Fakhar M, Tavakoli G, Nazar E, Kiani M. Molecular identification of leishmania species isolated from patients with cutaneous leishmaniasis in Pakdasht district, Iran, 2009–2014. *J Mazandaran Univers Med Sci.* (2016) 26:241–6. Available online at: <http://jmums.mazums.ac.ir/article-1-9018-en.html>
  115. Rezaei A, Moghaddas E, Bagherpor MR, Naseri A, Shamsian SA. Identification of leishmania species for cutaneous leishmaniasis in Gonbad, Bardaskan and Kashmar, central Khorasan, 2015. *Jundishapur J Microbiol.* (2017) 10:e44469. doi: 10.5812/jjm.44469
  116. Kermanjani A, Akhlaghi L, Oormazdi H, Hadighi R. Isolation and identification of cutaneous leishmaniasis species by PCR-RFLP in Ilam province, the west of Iran. *J Parasitic Dis.* (2017) 41:175–9. doi: 10.1007/s12639-016-0772-7
  117. Mohammadi A, Dalimi A, Mahmoodi MR, Parian M, Pirestani M, Mohebbali M. The PCR-RFLP-based detection and identification of the *Leishmania* species causing human cutaneous leishmaniasis in the

- Khorasan-Razavi Province, Northeast of Iran. *J Arthropod Borne Dis.* (2017) 11:383–92.
118. Nemati S, Fazaeli A, Hajjaran H, Khamesipour A, Anbaran MF, Bozorgomid A, et al. Genetic diversity and phylogenetic analysis of the Iranian *Leishmania* parasites based on HSP70 gene PCR-RFLP and sequence analysis. *Kor J Parasit.* (2017) 55:367. doi: 10.3347/kjp.2017.55.4.367
  119. Motalleb G, Mirahmadi H, Ahmad Z-Z, Mehravaran A. Cytochrome b and Molecular Typing of *Leishmania* spp. in a Passive Sampling of Suspected Patients with Cutaneous Leishmaniasis in Sistan and Baluchestan Province, Eastern Iran. *Iran J Parasit.* (2017) 12:534.
  120. Rastaghi ARE, Spotin A, Khataminezhad MR, Jafarpour M, Alaeenovin E, Najafzadeh N, et al. Evaluative assay of nuclear and mitochondrial genes to diagnose leishmania species in clinical specimens. *Iran J Public Health.* (2017) 46:1422.
  121. Behravan M, Moïn-Vaziri V, Haghghi A, Rahbarian N, Taghipour N, Abadi A, et al. Molecular identification of *Leishmania* species in a re-emerged focus of cutaneous leishmaniasis in Varamin district, Iran. *J Arthropod-Borne Dis.* (2017) 11:124.
  122. Mohammadpour I, Motazedian MH, Handjani F, Hatam GR. Lip leishmaniasis: a case series with molecular identification and literature review. *BMC Infect Dis.* (2017) 17:96. doi: 10.1186/s12879-016-2178-7
  123. Saghaipour A, Vatandoost H, Zahraei-Ramazani AR, Yaghoobi-Ershadi MR, Jooshin MK, Rassi Y, et al. Epidemiological study on cutaneous leishmaniasis in an endemic area, of Qom province, central Iran. *J Arthropod-Borne Dis.* (2017) 11:403–13.
  124. Fata A, Rezai A, Moghaddas E, Mousavi VFS, Shamsian SA. Identification of Cutaneous Leishmaniasis Species in the Dargaz City, Iran. *J Isfahan Med School.* (2017) 34:1582–89. Available online at: <https://www.sid.ir/en/Journal/ViewPaper.aspx?ID=532733>
  125. Akia A, Hamzavi Y. Diagnosis and molecular typing of leishmania in patients with cutaneous leishmaniasis. *J Mazandaran Univer Med Sci.* (2017) 26:22–30. Available online at: <http://jmums.mazums.ac.ir/article-1-9636-en.html>
  126. Mirahmadi H, Rezaee N, Mehravaran A, Heydarian P, Raeghi S. Detection of species and molecular typing of *Leishmania* in suspected patients by targeting cytochrome b gene in Zahedan, southeast of Iran. *Vet World.* (2018) 11:700. doi: 10.14202/vetworld.2018.700-705
  127. Namazi MJ, Dehkordi AB, Haghghi F, Mohammadzadeh M, Zarean M, Hasanabad MH. Molecular detection of *Leishmania* species in northeast of Iran. *Comp Clin Pathol.* (2018) 27:729–33. doi: 10.1007/s00580-018-2658-9
  128. Teimouri A, Mohebbali M, Kazemirad E, Hajjaran H. Molecular identification of agents of human cutaneous leishmaniasis and canine visceral leishmaniasis in different areas of Iran using internal transcribed spacer 1 PCR-RFLP. *J Arthropod-Borne Dis.* (2018) 12:162. doi: 10.18502/jad.v12i2.42
  129. Zahirnia AH, Bordbar A, Ebrahimi S, Spotin A, Mohammadi S, Ghafari SM, et al. Predominance of *Leishmania major* and rare occurrence of *Leishmania tropica* with haplotype variability at the center of Iran. *Brazil J Infect Dis.* (2018) 22:278–87. doi: 10.1016/j.bjid.2018.07.005
  130. Ghatee MA, Mirhendi H, Marashifard M, Kannejad Z, Taylor WR, Sharifi I. Population structure of *Leishmania tropica* causing anthroponotic cutaneous leishmaniasis in southern Iran by PCR-RFLP of kinetoplastid DNA. *BioMed Res Int.* (2018) 2018:198. doi: 10.1155/2018/6049198
  131. Mousavi T, Shokohi S, Abdi J, Naserifar R, Ahmadi M, Mirzaei A. Determination of genetic diversity of *Leishmania* species using minicircle kDNA, in Iran-Iraq countries border. *Trop Parasit.* (2018) 8:77. doi: 10.4103/tp.TP\_3\_18
  132. Ramezany M, Sharifi I, Babaei Z, Ghasemi Nejad Almani P, Heshmatkhan A, Keyhani A, et al. Geographical distribution and molecular characterization for cutaneous leishmaniasis species by sequencing and phylogenetic analyses of kDNA and ITS1 loci markers in south-eastern Iran. *Pathogens Global Health.* (2018) 112:132–41. doi: 10.1080/20477724.2018.1447836
  133. Askari A, Sharifi I, Aflatoonian M, Babaei Z, Almani PGN, Mohammadi M, et al. A newly emerged focus of zoonotic cutaneous leishmaniasis in South-Western Iran. *Microbial Pathogen.* (2018) 121:363–8. doi: 10.1016/j.micpath.2018.04.053
  134. Mirzaei A, Ahmadipour F, Cannet A, Marty P, Delaunay P, Perrin P, et al. Immunodetection and molecular determination of visceral and cutaneous *Leishmania* infection using patients' urine. *Infecti Genet Evolut.* (2018) 63:257–68. doi: 10.1016/j.meegid.2018.05.021
  135. Fata A, Moghaddas E, Rezee A, Abdali A, Jarahi L, Shamsian A. Epidemiological study of cutaneous leishmaniasis and identification of etiological species. *J Mazandaran Univer Med Sci.* (2018) 27:123–31. Available online at: <http://jmums.mazums.ac.ir/article-1-10299-en.html>
  136. Gholamian-Shahabad MR, Azizi K, Asgari Q, Kalantari M, Moemenbellah-Fard MD. Sandflies species composition, activity, and natural infection with *Leishmania*, parasite identity in lesion isolates of cutaneous leishmaniasis, central Iran. *J Paras Dis.* (2018) 42:252–8. doi: 10.1007/s12639-018-0994-y
  137. Mohammadiha A, Dalimi A, Mohebbali M, Sharifi I, Mahmoudi M, Mirzaei A, et al. Molecular identification and phylogenetic classification of *Leishmania* spp. isolated from human cutaneous leishmaniasis in Iran: a cross-sectional study. *Iran J Parasit.* (2018) 13:351.
  138. Mirzapour A, Spotin A, Behniafar H, Azizi H, Maleki B, Shakeraminia H, et al. Intra-Species Diversity of *Leishmania major* and *L. tropica* from Clinical Isolates of Cutaneous Leishmaniasis in Southwest Iran Inferred by ITS1-rDNA. *Iran J Public Health.* (2019) 48:893. doi: 10.18502/ijph.v48i5.1806
  139. Razavinasab SZ, Sharifi I, Aflatoonian MR, Babaei Z, Mohammadi MA, Salarkia E, et al. Expansion of urban cutaneous leishmaniasis into rural areas of southeastern Iran: clinical, epidemiological and phylogenetic profiles explored using 7SL high resolution melting-PCR analysis. *Transbound Emerg Dis.* (2019) 66:1602–10. doi: 10.1111/tbed.13186
  140. Mohammadpour I, Hatam GR, Handjani F, Bozorg-Ghalati F, PourKamal D, Motazedian MH. *Leishmania* cytochrome b gene sequence polymorphisms in southern Iran: relationships with different cutaneous clinical manifestations. *BMC Infect Dis.* (2019) 19:98. doi: 10.1186/s12879-018-3667-7
  141. Barazesh A, Motazedian MH, Fouladvand M, Hatam G, Tajbakhsh S, Ebrahimi S, et al. Molecular identification of species caused cutaneous leishmaniasis in southern zone of Iran. *J Arthropod-Borne Dis.* (2019) 13:198. doi: 10.18502/jad.v13i2.1246
  142. Ghobakhloo N, Motazedian MH, Naderi S, Ebrahimi S. Isolation of *Crithidia* spp. from lesions of immunocompetent patients with suspected cutaneous leishmaniasis in Iran. *Trop Med Int Health.* (2019) 24:116–26. doi: 10.1111/tmi.13042
  143. Mirahmadi H, Gholizadeh S, Raeghi S, Sadat Roointan E, Rezaee N, Mehravaran A. kDNA and molecular typing of *leishmania* spp. Of cutaneous leishmaniasis patients in sistan and baluchestan province with low amount of parasite. *J KermanUnivers Med Sci.* (2019) 26:1–11. doi: 10.22062/jkmu.2019.87269
  144. Ziaei Hezarjaribi H, Emadi N, Asfaram S, Geran Orimi T, Derakhshani-niya M, Fakhar M. Molecular Detection of *Leishmania* spp. in Negative Smears of Patients with Cutaneous Leishmaniasis in Bam, Southeast Iran. *J Mazandaran Univer Med Sci.* (2019) 29:123–7. Available online at: <http://jmums.mazums.ac.ir/article-1-12648-en.html>
  145. Zare-Zadeh A, Motalleb G, Mirahmadi H, Salimi Khorashad A. ITS-rDNA and molecular typing of *Leishmania* spp. in suspected patients with cutaneous leishmaniasis in Sistan and Balochestan province, Iran. *J Cell Mol Res.* (2019) 32:125–35. Available online at: <http://magiran.com/p1996206>
  146. Sarkari B, Fakhar M, Ebrahimi M, Hatam G, Kalantari M, Rezaeejad H. Characterization of *Leishmania* parasites isolated from Kala-azar patients in Kohgiluyeh and Boyer-Ahmad, using semi-nested PCR. *Armaghane Danesh.* (2006) 11:27–34. Available online at: <https://www.sid.ir/en/journal/ViewPaper.aspx?id=62124>
  147. Alborzi A, Rasouli M, Shamsizadeh A. *Leishmania tropica*—isolated patient with visceral leishmaniasis in southern Iran. *Am J Trop Med Hyg.* (2006) 74:306–7. doi: 10.4269/ajtmh.2006.74.306
  148. Motazedian M, Fakhar M, Motazedian MH, Hatam G, Mikaeili F. A urine-based polymerase chain reaction method for the diagnosis of visceral leishmaniasis in immunocompetent patients. *Diagn Microb Infect Dis.* (2008) 60:151–4. doi: 10.1016/j.diagmicrobio.2007.09.001
  149. Alborzi A, Pouladfar GR, Fakhar M, Motazedian MH, Hatam GR, Kadivar MR. Isolation of *Leishmania tropica* from a patient with visceral leishmaniasis and disseminated cutaneous leishmaniasis, southern Iran. *Am J Trop Med Hyg.* (2008) 79:435–7. doi: 10.4269/ajtmh.2008.79.435
  150. Fayzi M, Fanid L, Fayzi A, Pour M, Farajnia S, Nakhilband A. Detection of *Leishmania infantum* minicircle kinetoplast DNA in bone marrow and peripheral blood samples of paediatric patients from children's hospital of Tabriz Medical University. *Biotechnology.* (2008) 7:175–81. doi: 10.3923/biotech.2008.175.181

151. Fakhar M, Keyghobadi M, Akramipour R, Ghadiri K, Limouei M. Characterization of *Leishmania* isolated from Kala-azar infected patients in Kermanshah using PCR. *J Kermanshah Univ Med Sci.* (2011) 15:138–44.
152. Fakhar M, Motazedian M, Hashemi S, Golkar A. Detection of *Leishmania* parasites species isolated from patients suffering from kala-azar using one-step PCR. *J Jahrom Univers Med Sci.* (2011) 9:21–6. doi: 10.29252/jmj.9.2.21
153. Mohammadiha A, Mohebal M, Haghighi A, Mahdian R, Abadi A, Zarei Z, et al. Comparison of real-time PCR and conventional PCR with two DNA targets for detection of *Leishmania* (*Leishmania*) infantum infection in human and dog blood samples. *Exp Parasit.* (2013) 133:89–94. doi: 10.1016/j.exppara.2012.10.017
154. Fakhar M, Kia AA, Gohardehi S, Sharif M, Mohebal M, Akhoundi B, et al. Emergence of a new focus of visceral leishmaniasis due to *Leishmania infantum* in Golestan Province, north-eastern of Iran. *J Paras Dis.* (2014) 38:255–9. doi: 10.1007/s12639-013-0307-4
155. Hosseini-nasab A, Sharifi I, Mohammad Hossein D, Zarean M, Dadkhah M. Causes of pediatric visceral leishmaniasis in southeastern Iran. *Iran J Parasit.* (2014) 9:584.
156. Ghasemian M, Gharavi MJ, Akhlaghi L, Mohebal M, Meamar AR, Aryan E, et al. SYBR green-based detection of *Leishmania infantum* DNA using peripheral blood samples. *J Paras Dis.* (2016) 40:81–7. doi: 10.1007/s12639-014-0452-4
157. Sarkari B, Ahmadvpour NB, Moshfe A, Hajjaran H. Molecular evaluation of a case of visceral leishmaniasis due to *Leishmania tropica* in Southwestern Iran. *Iran J Parasit.* (2016) 11:126.
158. Asfaram S, Fakhar M, Mohebal M, Mardani A, Banimostafavi ES, Hezarjaribi HZ, et al. Asymptomatic human blood donors carriers of *Leishmania infantum*: potential reservoirs for visceral leishmaniasis in northwestern Iran. *Transf Apheresis Sci.* (2017) 56:474–9. doi: 10.1016/j.transci.2017.06.001
159. Asfaram S, Pagheh A, Fakhar M, Gheraghali F, Rezai MS. Case series of visceral Leishmaniasis (kala-azar) in mazandaran and golestan provinces, North of Iran. *J Mazandaran Univer Med Sci.* (2017) 26:373–81. Available online at: <http://jmums.mazums.ac.ir/article-1-9282-en.html>
160. Dalimi A, Mohammadiha A, Mohebal M, Mirzaei A, Mahmoudi M. Molecular identification and intra-species variations among *Leishmania infantum* isolated from human and canine visceral leishmaniasis in Iran. *Iran J Parasit.* (2018) 13:567.
161. Masoori L, Kheirandish F, Haghighi A, Mohebal M, Akhoundi B, Taghipour N, et al. Molecular-based detection of *Leishmania infantum* in human blood samples in a new focus of visceral leishmaniasis in Lorestan Province, Iran. *J Arthropod-Borne Dis.* (2018) 12:67.
162. Layegh Gigloo A, Sarkari B, Rezaei Z, Hatam GR, Davami MH. Asymptomatic *Leishmania* infected children: a seroprevalence and molecular survey in a rural area of Fars Province, Southern Iran. *J Trop Med.* (2018) 2018:7247. doi: 10.1155/2018/8167247
163. Rezaei Z, Sarkari B, Dehghani M, Gigloo AL, Afrashteh M. High frequency of subclinical *Leishmania* infection among HIV-infected patients living in the endemic areas of visceral leishmaniasis in Fars province, southern Iran. *Parasit Res.* (2018) 117:2591–5. doi: 10.1007/s00436-018-5949-9
164. Ghaee MA, Mirhendi H, Karamian M, Taylor WR, Sharifi I, Hosseinzadeh M, et al. Population structures of *Leishmania infantum* and *Leishmania tropica* the causative agents of kala-azar in Southwest Iran. *Parasitol Res.* (2018) 117:3447–58. doi: 10.1007/s00436-018-6041-1
165. Kumar A, Pandey SC, Samant M. DNA-based microarray studies in visceral leishmaniasis: identification of biomarkers for diagnostic, prognostic and drug target for treatment. *Acta Tropica.* (2020) 2020:105512. doi: 10.1016/j.actatropica.2020.105512
166. Shirzadi M, Gouya M. *National Guidelines for Cutaneous Leishmaniasis Surveillance in Iran*. Tehran Iran: Ministry of Health and Medical Education (MOH) Zoonoses Control Department (2012). p. 1–78.
167. Norouzzinezhad F, Ghaffari F, Norouzzinejad A, Kaveh F, Gouya MM. Cutaneous leishmaniasis in Iran: results from an epidemiological study in urban and rural provinces. *Asian Pacif J Trop Biomed.* (2016) 6:614–9. doi: 10.1016/j.apitb.2016.05.005
168. Foroutan M, Khademvatan S, Majidiani H, Khalkhali H, Hedayati-Rad F, Khashaveh S, et al. Prevalence of *Leishmania* species in rodents: a systematic review and meta-analysis in Iran. *Acta Trop.* (2017) 172:164–72. doi: 10.1016/j.actatropica.2017.04.022
169. Karimi T, Sharifi I, Aflatoonian MR, Aflatoonian B, Mohammadi MA, Salarkia E, et al. A long-lasting emerging epidemic of anthroponotic cutaneous leishmaniasis in southeastern Iran: population movement and peri-urban settlements as a major risk factor. *Parasit Vect.* (2021) 14:1–4. doi: 10.1186/s13071-021-04619-3
170. del Giudice P, Marty P, Lacour JP, Perrin C, Pralong F, Haas H, et al. Cutaneous leishmaniasis due to *Leishmania infantum*: case reports and literature review. *Arch Dermat.* (1998) 134:193–8. doi: 10.1001/archderm.134.2.193
171. Lachaud L, Dedet JP, Marty P, Faraut F, Buffet P, Gangneux JP, et al. Surveillance of leishmaniasis in France, 1999 to 2012. *Eurosurveillance.* (2013) 18:20534. doi: 10.2807/1560-7917.ES2013.18.29.20534
172. De Lima H, Rodríguez N, Feliciangeli MD, Barrios MA, Sosa A, Agrela I, et al. Cutaneous leishmaniasis due to *Leishmania chagasi/Le. infantum* in an endemic area of Guarico State, Venezuela. *Trans R Soc Trop Med Hyg.* (2009) 103:721–6. doi: 10.1016/j.trstmh.2008.11.019
173. Rostamian M, Bashiri H, Yousefinejad V, Bozorgomid A, Sohrabi N, Raeghi S, et al. Prevalence of human visceral leishmaniasis in Iran: a systematic review and meta-analysis. *Comp Immunol Microb Infect Dis.* (2020) 2020:101604. doi: 10.1016/j.cimid.2020.101604
174. Ghatee MA, Taylor WR, Karamian M. The geographical distribution of cutaneous leishmaniasis causative agents in Iran and its neighboring countries, a review. *Front Public Health.* (2020) 8:11. doi: 10.3389/fpubh.2020.00011
175. Reimão JQ, Coser EM, Lee MR, Coelho AC. Laboratory diagnosis of cutaneous and visceral leishmaniasis: current and future methods. *Microorganisms.* (2020) 8:1632. doi: 10.3390/microorganisms8111632
176. de Moraes RCS, de Melo MGN, de Goes TC, e Silva RP, de Moraes RF, de Oliveira Guerra JA, et al. Duplex qPCR for *Leishmania* species identification using lesion imprint on filter paper. *Exp Parasit.* (2020) 219:108019. doi: 10.1016/j.exppara.2020.108019
177. Sundar S, Singh OP. Molecular diagnosis of visceral leishmaniasis. *Mol Diagn Therapy.* (2018) 22:443–57. doi: 10.1007/s40291-018-0343-y
178. Dávila A, Momen H. Internal-transcribed-spacer (ITS) sequences used to explore phylogenetic relationships within *Leishmania*. *Ann Trop Med Parasit.* (2000) 94:651–4. doi: 10.1080/00034983.2000.11813588
179. Vega-López F. Diagnosis of cutaneous leishmaniasis. *Curr Opin Infect Dis.* (2003) 16:97–s101. doi: 10.1097/00001432-200304000-00006
180. Lorenz TC. Polymerase chain reaction: basic protocol plus troubleshooting and optimization strategies. *JoVE.* (2012) 2012:e3998. doi: 10.3791/3998
181. Saberi R, Fakhar M, Mohebal M, Anvari D, Gholami S. Global status of synchronizing *Leishmania* RNA virus in *Leishmania* parasites: a systematic review with meta-analysis. *Transbound Emerg Dis.* (2019) 66:2244–51. doi: 10.1111/tbed.13316
182. Ito MM, Catanhede LM, Katsuragawa TH, Silva Junior CF, Camargo LM, Mattos Rde G, et al. Correlation between presence of *Leishmania* RNA virus 1 and clinical characteristics of nasal mucosal leishmaniasis. *Braz J Otorhinolaryngol.* (2015) 81:533–40. doi: 10.1016/j.bjorl.2015.07.014
183. Saberi R, Fakhar M, Hajjaran H, Ataei-Pirkooch A, Mohebal M, Taghipour N, et al. Presence and diversity of *Leishmania* RNA virus in an old zoonotic cutaneous leishmaniasis focus, northeastern Iran: haplotype and phylogenetic based approach. *Int J Infect Dis.* (2020) 101:6–13. doi: 10.1016/j.ijid.2020.08.033

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Hajjaran, Saberi, Borjian, Fakhar, Hosseini, Ghodrati and Mohebal. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.